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Abstract
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter
significant delays before being tested in patients with cancer. While some of these delays have a scientific basis,
others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as
it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical
application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an “Immunotherapy
Summit” with representatives from immunotherapy organizations representing Europe, Japan, China and North
America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the
concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective
translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be
developed to make recommendations vetted by the participating organizations. These recommendations could
then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies
and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based
cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized
as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles
impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to
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specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical
translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of
patients with cancer.
Introduction
Globally, cancer claimed an estimated 7.6 million lives
in 2008 and is on pace to double that number by 2030
[1]. The impact of this disease on humanity is difficult
to measure. The Milken Institute estimates that in the
United States (US) alone, a 1% reduction in cancer mor-
tality has an economic value of $500 billion [2]. Cur-
rently the National Cancer Institute (NCI), National
Institutes of Health (NIH), foundations, governments,
biotechnology and pharmaceutical companies around
the world are investing substantially in research to con-
quer this disease. Over the past decade, discoveries in
basic cancer research related to this investment have
provided an enormous number of insights, reagents,
drugs and clinical protocols with potential to signifi-
cantly improve cancer outcomes. Nowhere is this poten-
tial more striking and relevant to a wide spectrum of
human cancers than in research on cancer immunother-
apy, which has the capacity to provide durable clinical
responses in even the most challenging cancers. None-
theless, the translation of these discoveries from the
“bench to the bedside” has been painfully slow.
In an effort to accelerate translation of new develop-
ments in basic immunology into patients with cancer,
representatives from eight immunotherapy organizations
representing Europe, Japan, China and North America
(Figure 1) convened an “Immunotherapy Summit” at the
24th Annual Meeting of the International Society for
Biological Therapy of Cancer (iSBTc; now the Society
for Immunotherapy of Cancer, SITC). One of the con-
cepts raised by SITC and defined as critical by all parties
was the need to identify hurdles that impede effective
translation of cancer immunotherapy. Subsequently, ten
organizations (Figure 2) met again in late 2010 at the
25th Annual Meeting of SITC to discuss next steps and
to commit to regular conference calls. While this is an
important first step, identification of these hurdles is
just the beginning. The development of collaborative,
international working groups to identify solutions and
help remove these hurdles could increase the speed at
which novel, effective immunotherapy strategies reach
patients with cancer. That is the goal.
The hurdles identified by representatives of the (now
fifteen) collaborating organizations (Figure 3) can be
grouped into nine general themes (Table 1). In some
instances an identified hurdle is substantially intercon-
nected with another hurdle or set of hurdles. For exam-
ple, the lack of validated biomarkers further complicates
the design and evaluation of clinical trials that combine
immunotherapeutic agents. Thus efforts to address the
identified hurdles to the translation of cancer immu-
notherapy must be through a coordinated, integrated,
multidisciplinary and international approach.
What is Cancer Immunotherapy? Cancer immu-
notherapy is the original targeted therapy and includes
any strategy that utilizes the anticancer immune
response or components of the immune system, as can-
cer treatment. Seventeen immunotherapy products have
received FDA approval in the past quarter century [3].
These include non-specific stimulators, cytokines,
monoclonal antibodies, radiolabelled antibodies, immu-
notoxins, and cell-based therapy (reviewed in [3]).
Further, the recent observations that immune response,
Figure 1 2009 Immunotherapy Summit at SITC creating the
working group, National Harbor, MD, USA. Back row: Leif
Haakason, Sylvia Janetski, Franco Marincola, Lisa Butterfield, Hideaki
Tahara, Dolores Schendel, F Stephen Hodi, Heinz Zwierzina, A. Raja
Choudhury, Graham Pawlec, Wenru Song. Front row: Tom Gajewski,
Bernard A. Fox, Mary Disis, Michael Papamichail, Michael B. Atkins
Figure 2 2010 Immunotherapy Summit at SITC, Capital Hill,
Washington DC, USA. Back row: Michael Papamichail, Hideaki
Tahara, Howard Kaufman, Jedd Wolchok, Franco Marincola, James
Finke, Rejean Lapointe, Hyam I. Levitsky, George Coukos, Wenru
Song, Padmanee Sharma, F Stephen Hodi, Jim Allison, Lisa
Butterfield, William Murphy, Leif Haakson, A. Raja Choudhary, Heinz
Zwierzina, Yutaka Kawakami, Kohzoh Imai. Front row: Harpreet
Singh-Jasuja, Michele Maio, Paolo Ascierto, Giorgio Parmiani, Bernard
A. Fox, Axel Hoos, Tom Gajewski, Dolores Schendel, Cedrik Britten.
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characterized by immunohistochemistry, has better
prognostic power than standard staging systems under-
scores the importance the endogenous immune
response plays in patient outcomes and the potential
impact boosting this immune response has for increas-
ing survival [4,5]. These findings may help to recast the
current classification, and to identify the high-risk
patients who would benefit the most from adjuvant
therapy.
1. Limitations of Preclinical Animal Models
While preclinical animal models have provided the basis
for our understanding of immune function and signifi-
cant insights into the mechanisms that regulate thera-
peutic efficacy of immunotherapy, the current models
have not been consistent predictors for the efficacy of
cancer immunotherapy strategies that enter the clinic.
One reason for this disconnect may be that small, trans-
plantable tumors, established for 3-5 days in an animal
model, fail to recapitulate the complex, integrated
pathophysiological setting, in which patients can have a
large tumor burden that they have lived with for months
to years. Models that utilize advanced or spontaneous
tumors may begin to address this shortcoming. Another
limitation is the inherent “immunogenicity” of the
tumor model used. Experiments with tumors expressing
xenogeneic proteins are frequently coupled with trans-
genic T cells to address basic questions about T cell
trafficking, cytokine profiles and clonal expansion, in
addition to many other scientific questions relevant to
understanding the immunological response to tumors.
However, given the foreign nature of the xenogeneic
protein and the ease with which an immune response
can be generated against these targets in wild type (WT)
mice, these tumors are considered inadequate for mod-
eling the human immune response to immunotherapy
strategies. In other cases, the use of transplantable
tumors without xenogeneic protein constructs may be
useful. Further, many of the frequently used tumor cell
lines were generated 20 - 40 years ago; given the genetic
drift possible in 100 generations, the inbred mice may
exhibit substantial histocompatibility differences that
can result in these tumors being more immunogenic
today than when they were originally developed, poten-
tially limiting their usefulness as models of human dis-
ease. Another limitation is that the vast majority of
studies are done in genetically identical inbred animals
that do not represent the genetic diversity found in
humans or in young mice, lacking the impact of aging
on the immune system [6]. Some therapeutic interven-
tions are tested in human xenograft models in immune-
deficient mice, in which effects on and by the immune
system are not addressed [7]. Human xenograft models
in which human immune cells are also transferred are a
potential improvement [8], although the reality of a fully
functional human immune system in a mouse is still far
away. Recently, severely immunodeficient mouse strains
have been developed such as NOD.Cg-Prkdcscid
IL2rgtmWjl/Sz (NOD/SCID/IL-2Rgnull or NSG), which
can be reconstituted with a human hematopoietic sys-
tem through engraftment of human cord blood CD34+
cells [9]. These offer unique opportunities to study
human grade immunomodulatory reagents. The devel-
opment of spontaneous tumor models in transgenic
Figure 3 2011 Immunotherapy Summit at SITC, North
Bethesda, MD, USA. Back row: Michele Maio, Michael Papamichail,
Michael Nishimura, Bernard A. Fox, Andrea Nicolini, Jens-Peter
Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro Sasada,
Yutaka Kawakami, Rejean Lapointe, Christoph Huber, Jonathan L.
Bramson, Pawel Kalinski, Paolo Ascierto, Giuseppe Masucci, Heinz
Zwierzina, Franco Marincola, F Stephen Hodi, Per Thor Straten,
Jianda Yuan, Front row: Samir Khleif, Lisa Butterfield, Tom Gajewski,
Graham Pawlec, Pam Ohashi, Cornelius Melief, Cedrik Britten.
Table 1 Critical Hurdles in Cancer Immunotherapy Identified by SITC and Collaborating Associations
1. Limitations of current animal models to predict efficacy of cancer immunotherapy strategies in humans
2. Prolonged time to obtain approval to initiate clinical trials
3. Complexity of cancer, tumor heterogeneity and immune escape
4. Limited availability of reagents for combination immunotherapy studies
5. Limited funds available to translate science into patients
6. Lack of definitive biomarker(s) for assessment of clinical efficacy of cancer immunotherapies
7. Conventional clinical response criteria do not take into consideration differences between response patterns to cytotoxic agents and
immunotherapies
8. Paucity of teams of scientists and clinicians dedicated to translational research in cancer immunotherapy
9. Insufficient exchange of information critical to advancing the field
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mice (in which animals are tolerant to genes used to
induce the malignant event) offer multiple advantages
over transplantable tumors for many applications. The
tumors in models using genetically engineered mice
(GEM) often develop similar defects in the tumor
microenvironment, limiting host immune responses.
Moreover, tumor growth is quite heterogenic mimicking
human tumors. The heterogenic phenotype of most
GEM models requires larger numbers of animals to be
studied to assess significance of the intervention. Unfor-
tunately, the cost of generating and maintaining trans-
genic colonies of GEM can be prohibitive for many
investigators. In addition, these models are usually based
on the tissue-specific expression of a strong driver onco-
gene, which may overwhelm the immune-surveillance
and immune-editing steps of cancer development. One
example of an alternative approach to integrate an onco-
genic signal in tissue has been recently reported [10].
Hydrodynamic co-delivery of genes encoding b-catenin
(CAT) and MET or AKT induced steatotic hepatocellu-
lar adenomas that transitioned to hepatocellular carcino-
mas (HCC) or led to rapid induction of HCC,
respectively. This innovative approach overcomes many
of the afore mentioned limitations by providing a rapid
and relatively inexpensive method for generating sponta-
neous tumors in mice of a specific MHC background, in
specific gene knock-out, transgenic, or aged mice.
Together the preclinical models remain an important
“proving ground” for some classes of immunotherapies
and for the evaluation of possible synergies with combi-
nation immunotherapies. While imperfect, advanced and
spontaneous tumor models are still considered to be
more useful than in vitro studies at informing clinical
trial designs of novel agents and combination
immunotherapy.
With regard to predicting safety of novel antigen-
based cancer immunotherapies by using animal models,
numerous limitations exist. Vaccination with antigens
relies on the species- (and allele-) specific binding of
antigen to human leukocyte antigen (HLA) receptors (in
the case of short peptide antigens) and species-specific
processing of antigens by a complicated interplay invol-
ving different proteasome species, other proteases, heat
shock proteins, TAP transporter and finally, again, bind-
ing to HLA receptor (in the case of protein, long pep-
tide, RNA or DNA vaccines). Even if mice were
generated that expressed the appropriate HLA type and
the human antigen sequences, such models might not
adequately predict safety or autoimmune effects based
on the diversity of the other components of antigen pro-
cessing machinery involved.
Preclinical animal studies have also been used to
assess potential toxicity of immunologically active
agents. In the absence of in vivo preclinical data, in-
vitro assays have been used to identify the ‘minimum
anticipated biological effect level’ (MABEL). A recent
report offers a protocol that provides increased sensitiv-
ity to detect soluble T cell stimulants [11]. Alternatively,
micro dosing or flat dose escalation studies have been
proposed. The lethal toxicity associated with chimeric
antigen receptor (CAR) gene-modified T cells is an
example where a preclinical model did not exist to
appropriately test the potential toxicity [12,13]. The two
reported cases led to both National Institutes of Health
(NIH) and the US Food and Drug Administration (FDA)
review and resulted in modifications to clinical trial
design where the dose of adoptively transferred gene-
modified T cells is escalated from a much lower dose
than where toxicity was observed. As new agents and
combinations of immunotherapies are evaluated, flexibil-
ity of the regulatory agency providing oversight will be
critical for the efficient translation of these strategies to
patients.
Opportunities
Could standards be suggested for investigators using
preclinical models to improve the utility or interpreta-
tion of animal studies? Are there other instances when
proof-of-concept studies in animals can be waived?
Additionally, the limitation of assessing toxicity of
immunological agents, specifically monoclonal antibo-
dies, in non-human primates has been raised at several
SITC conferences. These studies, due to their high cost,
limit the number of agents that are moved to the clinic.
How often are such studies instructive of clinical toxici-
ties and when is it appropriate to discuss with regulatory
agencies the elimination of these studies?
2. Delayed Institutional, Administrative and Regulatory
Approval
The time to obtain approval to initiate a clinical trial has
been identified as a critical hurdle for some investiga-
tors. In the global science community there are aca-
demic institutions where administrative review can add
as much as seven months to the approval process. At
other centers, thanks in part to standardized procedures
and protocols, and institutional familiarity with the pro-
posed investigational strategies, administrative and insti-
tutional review board (IRB) approval can be obtained
relatively quickly. Consistent with the difficulties per-
ceived in the U.S. to open trials, there has been a large
movement of cancer trials to Europe and Asia due to
the slow activation of trials in the U.S.
With regards to regulatory approval within the US,
FDA reviewers must respond to the application for an
investigational new drug (IND) within 30 days of sub-
mission. While this efficient review process provides no
guarantee for rapid approval, the feedback that the
agency provides, sometimes prior to the 30 day window,
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allows for modifications that can sometimes resolve
issues and avert a clinical hold on the application.
Health Canada employs the same 30 day rule for review
of clinical trials. Similarly, the European Medicines
Agency (EMA) has the option of an accelerated review
procedure for products of major therapeutic interest. In
contrast, regulatory agencies in some countries may take
a year or more to approve a comparable application.
Another major difference between nations is the dis-
parity in production requirements for the biologics or
drugs used in the clinical trials. In the US, FDA exempts
most Phase 1 drugs, including biologics, to adhere to
Current Good Manufacturing Practice (cGMP) regula-
tions [14]. In contrast, the European Union has imple-
mented a rule that all early phase studies must be
performed under GMP. While the use of GMP in the
European Union is thought to have increased the quality
of clinical trials, especially of investigator-initiated trials,
it has clearly added significant cost and limited the
capacity of many academic institutions to perform trans-
lational cancer immunotherapy trials.
Opportunities
A cost-benefit analysis of restrictions that limit transla-
tion of novel therapies to patients with advanced cancer
may be appropriate. Are there other processes, short of
GMP, that might be employed to increase quality but
not the cost of some early phase clinical trials? This is a
particularly important issue since there is great variabil-
ity in access to facilities that function using cGMP and
GMP guidelines that also have the technologies available
to produce novel biologics developed by academia. Even
when a facility can be identified, traditional funding
mechanisms rarely pay for the production of the new
biologic.
3. Complexity of Cancer, Tumor Heterogeneity and
Immune Escape
Clearly cancer is a complex problem and this complexity
has been identified as a critical hurdle to the application
of cancer immunotherapy. The heterogeneity of the cells
making up the cancer and their propensity to develop
resistance to any form of therapy is well established
[15,16]. Further, histology results suggest that a specific
cancer, for example melanoma, is not a single disease,
but likely 13 or more different diseases [17], all of which
may ultimately be found to respond uniquely to thera-
peutic interventions [18]. Also, local stromal non-cancer
cells have a direct influence on tumor progression and
outcome [19], illustrating the complexity of tumor
microenvironment. In addition to the potential hetero-
geneity within each tumor is the likelihood that tumor
at each metastatic site is heterogeneous in expression of
antigens, or lack thereof, and/or escape mechanisms;
substantially increasing the complexity of the disease in
each patient far beyond the simple categorization of that
disease.
On top of the complexities directly related to the
tumor are variables that can influence a patient’s ability
to generate and maintain an effective antitumor immune
response. A major factor in this setting is the overall
immune status of the patient. This is influenced by age,
previous therapeutic interventions as well as by elements
directly and/or indirectly related to the tumor. The sta-
tus of the patient’s immune system and its impact on
clinical outcome has important implications for the
identification of host-related prognostic markers, of
host-related predictive markers to classical chemothera-
pies and radiotherapies as well as that of novel innova-
tive immunotherapies. Unfortunately, there is no
consensus on a biomarker(s) for assessing immune sta-
tus of individuals enrolling in immunotherapy trials
[20], however this should not prevent investigators from
incorporating novel strategies to assess immune compe-
tence of patients enrolling in trials. Recent reports sug-
gest that the immune signature at the tumor site,
characterized by genetic or histological assessment, may
predict responsiveness to therapy [21,4]. Additional stu-
dies have also shown that pre-surgical clinical trials can
be used as a mode of investigating the impact of immu-
notherapeutic agents on human immune responses in
both the systemic circulation and tumor microenviron-
ment, thus providing a feasible platform on which to
obtain crucial data that can then be applied to larger
clinical trials [22,23]. Support for these types of Phase Ia
or Phase IIa trials [24], which are designed to investigate
mechanisms and biologic endpoints, is necessary in
order to identify potential biomarkers that correlate
with benefit or resistance to therapy.
While additional validation is required, these observa-
tions are encouraging investigators to redouble their
efforts to assess immune competence of patients enter-
ing immunotherapy trials. Also important to these
efforts, is the need to encourage testing of new agents
in the neo-adjuvant setting to allow improved assess-
ment of potential biomarkers of early response.
Another level of complexity is the ability of cancer
cells, under the selective pressure of an antitumor
immune response, to shed targets or accessory mole-
cules in ways that allow them to evade detection and
killing by immune cells [25-27]. Alternatively, tumors
may express inhibitory molecules that impair the antitu-
mor immune response and limit the impact of the ther-
apeutic intervention. While the complexity of this
problem is considered a critical hurdle, appreciating this
complexity and designing therapeutic combinations to
augment immune responses and neutralize escape
mechanisms holds substantial promise for improving the
effectiveness of cancer immunotherapy.
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Opportunities
Since the characterization of tumors prior to and follow-
ing immunotherapy has not been well studied, the con-
sortium might encourage a multicenter evaluation of
such specimens. This could include the development of
a taskforce to provide input on a global standardization
of the tumor microenvironment. In support of this con-
cept on October 24-25, 2012, SITC will provide oppor-
tunities for the consortium to gather in North Bethesda
for a two-day workshop on evaluation of the tumor
microenvironment. Performing systematic biopsies of
tumor lesions considered as representative targets
should also be considered and ethically admitted in
most protocols to allow a dynamic characterization of
immunomodulation. Further, modifications to some
informed consent documents should be considered to
ensure that patient specimens could be used to aid bio-
marker development. Additionally, better identification
of major immune defects in patient groups may lead to
more appropriate therapies.
4. Limited Availability of Reagents for Combination
Immunotherapy Studies
While many preclinical studies have documented signifi-
cant synergies and improved outcomes when immu-
notherapy is combined with a wide range of agents,
trials with combined agents may present additional
complexities and risks to the drug developer and
patient. One problem is the classical method to find the
maximum tolerated dose (MTD) in phase I studies. Bio-
logical products, in particular vaccines, have less toxicity
and may have a bell-shaped dose immune response
curve. This has promoted the idea of dosing based on
biological activity assessed by a biomarker.
Opportunities
Developing a strategy that takes into consideration both
toxicity grade and the “immune response score” could
provide an optimal biologically active dose. While some
investigators are implementing such strategies into their
studies, consensus on this matter would likely aid the
implementation of combination immunotherapy trials.
It is becoming increasingly apparent that many stan-
dard cancer treatments may enhance the effectiveness of
immunotherapy, possibly due to increased inflammation,
release of antigen and danger signals, immunogenic cell
death pathways and dampening the effects of regulatory
cells. Indeed, many investigators are exploring immu-
notherapy combinations with other immunotherapeutic
agents, biologicals, targeted therapeutics, chemotherapy,
radiation and/or surgery as promising strategies to
improve cancer outcomes [28-32]. This enthusiasm has
been driven by the appreciation that even agents long
thought to work solely on tumor cells can have potent
effects on the anti-cancer immune response.
For agents that are already approved, the hurdle may
simply be limited resources or high costs necessary to
acquire the specified treatment for a combination study
unless the company marketing the product is willing to
supply the agent for the study. However, for agents that
are in early/late phase clinical trials and are not already
approved, pharmaceutical sponsors may not want the
added risk that the combination trial may interfere with
their drug development and registration plan. One con-
cern is that a novel strategy employing company A’s
agent X in combination with company B’s agent Y, may
result in a severe adverse event (SAE) that raises regula-
tory concerns about either drug, X or Y, as a single regi-
men. This may prompt additional patient safety
monitoring requirements in all ongoing trials with drug
X or Y, which pose particular challenges if either drug is
in large, multi-national registration trials. Given the
SAEs that have been observed with single agents (IL-2,
anti-CTLA-4) and the limited experience with combin-
ing immune-potentiating biologicals, [33-35] there exists
the possibility that combinations may increase toxicity.
However, the potential to improve efficacy significantly,
without concomitantly increasing toxicity, as has been
observed in preclinical and a few clinical studies, pro-
vides a compelling rationale for combining immune-
potentiating agents. It is important to continue the dis-
cussions in this area and try to agree upon a compro-
mise that will allow earlier testing of combinations
particularly in diseases that are in desperate need of
new therapies. Most cancers are not cured by one agent.
It is critical to take this into account and to work
toward developing a mechanism for testing combina-
tions where the scientific rationale supports the trial
design.
Other concerns surround the possibility that investiga-
tors could discover something that might limit the uti-
lity of that drug or obtain negative results that devalue
intellectual property (IP). Alternatively, mechanism of
action studies may lead to broad claims by the investiga-
tors, further limiting a company’s IP. Finally, integration
of clinical and regulatory operational efforts between
two companies poses challenges. These include selection
of only one of the companies or academic institutions
to hold the IND and assume full regulatory responsibil-
ity for a combination trial as well as dissemination of all
single agent IND safety reports from each company to
all investigators involved in the combination trial. If
these hurdles cannot be addressed, it will take much
longer to put together the “dream teams” of immunolo-
gical agents that many in our field are eager to evaluate
in the clinical setting based on synergisms observed in
preclinical studies. At the 2010 Collaboration Summit
on cancer immunotherapies hosted by SITC the ten par-
ticipating organizations agreed that promoting
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innovative trials of combinations is a high priority. Late
last year the NCI took constructive action by launching
the Cancer Immunotherapy Network (CITN), providing
a mandate to develop and conduct clinical trials with
prioritized immunotherapy agents alone or in rational
combinations [36-38]. While resources will be limited,
the CITN establishes a cooperative, multicenter frame-
work to advance a number of critical studies. But this is
not enough. More needs to be done to enable explora-
tory trials of immunotherapy combinations.
Opportunities
One strategy may be to increase the number of aca-
demic manufacturing facilities that could provide clinical
grade materials for clinical trials. Particularly for clinical
grade agents that large pharmaceutical companies are
not interested in and that small biotech may not be able
to distribute to all the potential partners involved. This
may be particularly helpful for vaccine components such
as recombinant proteins, synthetic peptides, TLR ago-
nists, etc. One solution would be to have GMP facilities
supported in academic institutions, for instance in the
pharmacy departments or faculties in universities or
medical centers. Another option would provide govern-
ment contracts to commercial laboratories to produce
such products. Finally, governments might encourage
corporations to more actively pursue these strategies by
offering patent extensions or other incentives.
Recognizing the importance of promoting investiga-
tions of immunotherapy combinations, in March 2011
the CIC hosted its Annual Meeting with Focus on Sche-
dule and Dose for Combination Therapies and in April,
the CCIC also reviewed aspects of combination immu-
notherapy at their 4th annual meeting. Additional meet-
ings were held throughout 2011 with a focus on ways to
improve immunotherapy outcomes. In May, CIMT met
in Mainz, Germany, for their 9th Annual meeting
entitled “Targeting Cancer: Road-Maps for Success”.
From June 30th until July 1st, The JACI met in Osaka
for a symposium on the “Current status and future pro-
spective of cancer immunotherapy”. In September,
CSCO and SITC hosted a joint cancer immunotherapy
session in Xiamen, China, and in October, TIBT met in
Jinan, China for their “12th National Tumor Biotherapy
Conference” and ESCII and NIBIT joined together in
Siena for “New Perspectives in the Immunotherapy of
Cancer”. Also in October, the PIVAC held their 11th
meeting on cancer vaccines in Copenhagen. In Novem-
ber, the SITC hosted their second workshop on the
science and logistics of combination therapy [39] and in
December, SITC joined with NIBIT and the Italian Mel-
anoma Intergroup in sponsoring “Melanoma research: a
bridge from Naples to the World”. In 2012 additional
meetings focused on cancer immunotherapy are
planned. In March the BDA will host their 11th
Biological Therapy of Cancer Conference in Munich
and TVACT will host their 18th annual meeting on
Cancer Immunotherapy in Chicago. In April the CIC
will host their annual colloquium outside Washington
DC and in May CIMT will host their 10th annual meet-
ing in Mainz. Early in 2012, the European Academy of
Tumor Immunology will start writing combinatorial
multicentric randomized Phase II trials associating aca-
demic GMP vaccines, immunogenic chemotherapy and
immune checkpoint blockade inhibitors so that multiple
institutions experienced in immunotherapy and immu-
nomonitoring may be able to conduct this enterprise.
While each organization will continue to pursue meet-
ings and activities that address the needs of their mem-
bers, the consortium of fifteen organizations, termed the
World Immunotherapy Council, will work to find areas
for collaboration and exchange of scientific information.
5. Limited Funds Available to Translate Science into
Patients
Once investigators have identified a novel immunother-
apy treatment, with compelling preclinical evidence to
support its potential as a treatment for patients with
cancer, the challenge of obtaining funding to initiate the
clinical trial becomes a rate-limiting barrier. In the USA,
reduction in funding by the National Cancer Institute
(NCI) has seriously impacted the movement of new
treatment strategies to the clinic. The Department of
Defense has a number of programs that support transla-
tional clinical trials and this has helped fill the gap. The
struggling biotech sector provides some help. In the
USA some of this is through the NIH-funded Small
Business Innovation Research (SBIR) and Small Business
Technology Transfer (STTR) programs that have pro-
vided needed resources for moving agents to clinical
trials. In other instances it is local and state govern-
ments, angel investors and philanthropy, more than high
risk-adverse venture capital, that support these early
phase trials. In the future it is expected that these
sources will continue to play an important role in mov-
ing innovative first-in-human studies, particularly of cel-
lular and combination immunotherapy studies, to
patients with cancer. Investigators in Europe, Canada
and Japan are also concerned about limited options to
obtain support for translating new immunotherapy stra-
tegies to the clinic. However, the Japanese Ministry of
Health, Labour and Welfare recently announced a fund
of 1.1 billion Japanese yen for cancer vaccine clinical
trials over the next 3 years. In China, the new 12th 5
year plan will provide broad support for translational
clinical trials. Nonetheless, the majority of investigators
and co-authors consider the difficulty in obtaining fund-
ing to initiate clinical trials to be a major hurdle for can-
cer immunotherapy.
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Opportunities
To effectively communicate the impact investment in
translational research and biotechnology/cancer immu-
notherapy has on the economic development of national
and local economies as well as to human health [2].
6. Lack of Definitive Biomarkers of Immune Response
The lack of validated biomarkers for monitoring the
development of an immune response following therapy
is another critical hurdle for the translation of cancer
immunotherapies. The iSBTc-SITC-/NCI/FDA Task-
force for Immunotherapy Biomarkers, composed of nine
societies and participating organizations, has addressed
this in detail [20,14]. Eight of the nine challenges identi-
fied by this Taskforce were related to immunological
monitoring considerations. These included issues that
should be optimized to obtain validated assays that can
provide a reliable platform to compare cancer immu-
notherapy trials. A ninth challenge related to the identi-
fication of biomarkers for cellular immunotherapy
products. These issues included:
1) Processing and storage of blood samples to bank
peripheral blood mononuclear cells (PBMC) and serum
for immunologic studies
2) Characterization of cellular products for therapy
3) Assay standardization and harmonization before
testing patient samples
4) Centralization of immunological monitoring
5) Standardized assays that should be used for clinical
trial antitumor immune response determination
6) How assay data should be analyzed for “responder”
and “non-responder” identification
7) Reporting immunological monitoring data in
publications
8) Validation of specific assays and/or analytes as bio-
markers of clinical response
9) Novel assays in development for immunological
testing of patients
Despite substantial efforts from many groups, immu-
nological monitoring is challenged by two central limita-
tions. First, we do not know which parameters of
immune responses are the most important in a clinical
response to immunotherapy; secondly, we do not know
which assays or sample source (i.e., blood, lymph node,
DTH site or tumor) are optimal to assess these para-
meters and correlate to efficacy. Indeed, the tumor-spe-
cific cellular immune response promoted by
immunization often has not correlated with clinical can-
cer regression [40,41]. A contributing reason may be the
inherent complexity of immune response assays, in con-
junction with variable assay protocols across clinical
trial laboratories, which results in high data variability
and limited reproducibility [42]. Through more than five
years of community-wide proficiency panels on the
most commonly used immune response assays (ELI-
SPOT, HLA-peptide multimers, ICS and CFSE) orga-
nized by the CIMT and CIC immune monitoring
consortia, it could be demonstrated that assay harmoni-
zation is an effective mechanism to reduce these limita-
tions [42-44]. Harmonization guidelines resulting from
this process are simple to implement, do not impose
standardized assay protocols on individual laboratories
and improve assay performance without stifling scienti-
fic creativity. Assay harmonization may provide a solu-
tion for non-validated biomarker assays to minimize
data variability and allow correlation of immune moni-
toring results with clinical outcomes [45].
Another major hurdle in biomarker identification is
the low clinical response rates that limit identification of
correlates with response to immunotherapies. Indeed,
when response rates to immunotherapy reach 50%, it
has been possible to identify a significant correlation
with objective clinical response in patients maintaining
at least 5% tumor-specific T cells in their peripheral
blood for at least two weeks [46]. Standardized immune
monitoring of large multi-institution trials has recently
allowed for statistically significant correlations of anti-
tumor immunity and clinical outcome [47].
Opportunities
Moving forward, the hurdles specified above will need to
be addressed. The report from the iSBTc-SITC/FDA/
NCI Taskforce on Immunotherapy Biomarkers [20]
builds on the NCI’s REMARK criteria [48] as well as
other more recent reports, e.g., MIFlowCyt, MIACA,
and MIATA [49-51]. Integration of standardized proce-
dures and internal controls as well as improved report-
ing practices will improve the ability to identify immune
biomarkers following immunotherapy and other
approaches which impact immunity. The group will
continue to promote discussion around the importance
of standardization and support educational programs
aimed at improving the ability to reproducibly assess
immunotherapy biomarkers.
7. Conventional Response Criteria May Not Reflect the
Patterns of Response to Immunotherapies
RECIST or modified WHO criteria have provided the
basis for evaluating whether patients with cancer
respond to therapy. These traditional criteria were
developed for cytotoxic therapies and evaluate reduction
in tumor burden following initiation of treatment. While
immune therapies have led to striking and rapid reduc-
tions in tumor burdens in some patients, others have
experienced progression prior to experiencing tumor
regression or have had stabilization of disease. In these
latter two instances, patients may ultimately recognize a
benefit in overall survival but not be identified as
responding to therapy based on conventional response
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criteria. This pattern of response to therapy has been
observed by many investigators but was not systemati-
cally captured due to absence of adequate response cri-
teria. In 2004, as part of a collaboration between the
iSBTc (now SITC) and the CVC (now CIC) to address
issues relevant to the development of cancer immu-
notherapy, both organizations formed the Cancer Vac-
cine Clinical Trial Working Group (CVCTWG), which
included participation from the FDA and NCI.
CVCTWG held several workshops between 2004 and
2005 with a concluding workshop jointly hosted by
CVC and SITC at the 2005 Annual Meetings of both
organizations. (http://www.sitcancer.org/meetings/am05/
workshop.php). These workshops and the resulting pub-
lication with input from more than 180 investigators
representing academia, NCI, FDA, and the biotech and
pharmaceutical sector, discussed how evaluation of a
clinical response to immunotherapy might be modified
from that for cytotoxic agents [52].
Following the 2005 meeting, both collaborative and
independent efforts of the CIC, CIMT and SITC took
place to continue addressing these issues. Involvement
from the NCI and FDA was included in many of these
discussions. The goal of these meetings was to: a) sum-
marize community knowledge, b) define challenges, and
c) offer directions for improvement through community
workshops. Resulting knowledge was used to systemati-
cally generate and analyze data to arrive at pertinent
improvements of conventional clinical endpoints. Four
main areas were addressed: 1) CIC and CIMT-CIP
immune monitoring proficiency panels including >80
international laboratories across the field defined har-
monization criteria to provide quality-control mechan-
isms and minimize data variability without standardizing
laboratory protocols with the ultimate aim to allow for
correlation with clinical endpoints [42,43,51,44]. 2) The
SITC-FDA Taskforce on Immunotherapy Biomarkers,
with input from 9 organizations, addressed the lack of
validated biomarkers for monitoring the development of
an immune response following therapy and identified 9
challenges critical for the translation of cancer immu-
notherapies [20] (see section “Lack of Definitive Biomar-
kers of Immune Response”. 3) Clinical patterns of
antitumor response for immunotherapeutic agents are
more complex than those of chemotherapy [52-55] and
adjustments to RECIST or WHO criteria to capture all
patterns should be considered. 4) The translation of an
immune response into clinical antitumor activity and
possible survival benefit takes time [56,53,54]. Therefore,
effects on patient survival may only be detectable several
months after treatment start, which may be reflected in
a delayed separation of Kaplan Meier curves. This
observation was made as part of a systematic review of
publicly available Phase 3 data from cancer
immunotherapy trials during a CVC workshop in 2006
[56]. The delayed separation of Kaplan-Meier survival
curves may be addressed through revised statistical
methods of non-proportional hazards [54,57].
The core aspects of these community recommenda-
tions were reviewed at a United States Food and Drug
Administration Workshop, which included participation
and presentations by both CIC and SITC representa-
tives, and were included in a draft guidance document
on “Clinical Considerations for Therapeutic Cancer Vac-
cines” [58]. This illustrates how the collaborative efforts
of community-based organizations can lead to an expan-
sion of immunotherapy clinical trials methodology sup-
porting further advances in the field.
Opportunities
The discussion on changes to response criteria needs to
continue. A recent report used patient outcomes follow-
ing treatment with ipilimumab, a monoclonal antibody
that blocks CTLA-4, to evaluate how proposed new
immune-related response criteria (irRC) compared to
RECIST or WHO criteria [55]. The important observa-
tions from that report were that four patterns of
response were all associated with favorable survival.
The four patterns of response to immunotherapy
were:
1) shrinkage in baseline lesions, without new lesions;
2) durable stable disease (in some patients followed by
a slow, steady decline in total tumor burden);
3) response after an increase in total tumor burden;
and
4) response in the presence of new lesions.
The conventional response criteria assumed that early
increase in tumor growth and/or development of new
lesions indicated progressive disease, which has become
synonymous with drug failure. For immunotherapeutic
agents, however, initial tumor growth or appearance of
new tumors does not necessarily reflect immunotherapy
failure nor long-term outcomes and survival. The new
irRC more accurately reflect the response patterns asso-
ciated with immunotherapies, and may permit more
comprehensive assessment of cancer immunotherapy
clinical trial results as well as provide guidance in the
clinical care of patients with cancer receiving immu-
notherapies. While these new irRC appear promising,
prospective evaluation of these criteria following treat-
ment with immune therapy is clearly warranted [57].
The FDA, who actively participated in many of these
discussions, agreed that cancer vaccines might require
considerable time in order to induce a therapeutic
response. To address this the FDA provided specific
recommendations for the clinical trial statistical analysis
plan in their “Draft Guidance for Therapeutic Cancer
Vaccines” [58]. It is important to note that the impact
on survival is still the gold standard employed by the
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US FDA and that is the basis for the recent approval of
sipuleucel-T and Yervoy [44,59]. While recent reports of
markers of an immune response correlating with out-
comes are encouraging, substantial opportunities remain
for the development of novel surrogate markers of anti-
cancer immunity that correlate with improved survival
[47,60].
8. Paucity of Translational Teams of Scientists and
Clinicians
While there are centers of excellence with teams of
investigators working to translate the latest technologies,
there are far too few for the number of diseases that
need to be targeted with promising immunotherapies.
This needs to be improved. Given the cost for drug
development, industry alone cannot be relied upon to
conduct all the early stage testing, particularly since aca-
demic translational investigator teams, close to both
basic and clinical science, are likely in the best position
to move “their” agent into the clinic. This requires an
investment in infrastructure. Depending on the class of
agent(s) and international setting, this may require sim-
ple clean rooms or a complete GMP facility. The neces-
sary infrastructure, however, is not simply bricks and
mortar, but human capital as well. Teams including reg-
ulatory staff for the substantial protocol and consent
development and approval steps, QA/QC support,
trained data managers and research nurses, in addition
to clinicians and scientists, are required to make this
work. Clinicians must be appropriately recognized for
the time and energy they spend participating in clinical
trials beyond their standard clinical duties (which are
often more profitable). A common sentiment is that
there is a dramatic shortage of clinicians with a commit-
ment to clinical research. This may be due to health sys-
tems that poorly valorize involvement of clinicians in
research. Another reason clinicians may not have devel-
oped a career path in immunotherapy may be linked to
the previous negative experience of cancer immunother-
apy. Perhaps the increasing momentum in the field will
spark enthusiasm for clinicians to train in this field.
Another limitation is the number of PhD scientists that
are trained and empowered to move their science to the
clinic. Recognition of this, particularly by the Howard
Hughes Medical Institute (Med into Grad Initiative) and
centers with NIH Clinical and Translational Science
Awards (CTSA) has led to development of programs
that are successfully targeting incoming PhD students in
hopes of developing translational investigators [61]. But
having clinical researchers and translational PhD scien-
tists alone is not sufficient. The ability to organize, lead,
motivate, meld and sustain multidisciplinary groups of
investigator in translational teams is considered a critical
hurdle for advancing cancer immunotherapies and has
been recently discussed [62]. Recognizing the essential
role that team science plays in translational cancer
immunotherapy, the SITC, in celebration of their 25th
anniversary, developed an award to recognize centers
that have excelled in this area and provided a significant
and sustained contribution over the past 25 years [63].
Another signatory organization for this document, the
Cancer Research Institute, has been a sustaining source
of support for the field of cancer immunology for close
to 60 years. Its Pre-doctoral and Post-doctoral Fellow-
ship Programs have trained thousands of immunologists
over multiple generations. More recently through its
partnership with the Ludwig Institute for Cancer
Research, its Cancer Vaccine Collaborative establishes
the needed infrastructure, reagent procurement, clinical
trials management, and funding to carry out coordinated
early-phase clinical trials aimed at developing therapeu-
tic cancer vaccines.
Opportunities
While the programs noted above provide a basis for
training and supporting team science, the majority of
Universities do not consider seriously these contribu-
tions when evaluating candidates for promotion and
tenure. Recognizing the contributions of teams to the
advance of translational medicine and human health
and developing a structure for evaluating these contribu-
tions is an opportunity for this consortium.
9. Need to Enhance Exchange of Information Critical to
Advancing the Field
Another component of this “team” hurdle is the
exchange of information. Given the increasing complex-
ity it is becoming less feasible for a single group to have
the detailed knowledge and resources to investigate,
analyze, select and implement the best strategies to
move forward in clinical trials for any given indication.
A possible solution to this hurdle may be to link clusters
of investigators with interest and experience with a
given tumor type. The histocompatibility/HLA field
might serve as an example for this concept. In that field,
participants from around the world supplied reagents,
ideas, practical work and shared projects to advance the
whole field of transplantation. As a whole, these investi-
gators made progress by helping the entire field through
specific input of work and resources, driving significant
advances over several decades. The success of these
interactions (workshops, exchanges, central repositories)
laid the foundation for bone marrow transplantation
and organ transplantation (kidney, heart, liver, lung), all
of which would not have been feasible through the
efforts of a single individual or organization, or even
one regional or national consortium.
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Opportunities
The CITN may be able to promote a similar activity as
it brings together multiple groups under the same
umbrella. Similarly, societies, primarily those repre-
sented by co-authors of this publication, could also play
a role in bringing together groups of like-minded inves-
tigators. Through its annual meeting, associated pro-
grams and other collaborative initiatives, the SITC is
committed to facilitating the exchange of information
and education among basic and translational research-
ers, clinicians, and young investigators to advance can-
cer immunotherapies. Importantly, SITC and the other
signatory organizations have initiated a process to join
together and develop collaborative projects to catalyze
continued success in cancer immunotherapy worldwide.
This group, tentatively designated the World Immu-
notherapy Council, will begin by approaching some of
the hurdles addressed in this document, and also by
organizing joint scientific meetings and sessions.
Conclusion
The identification of nine critical hurdles (Table 1) is an
important beginning for this group of collaborating
organizations focused on cancer immunotherapy. In late
2010, representatives of ten organizations met in
Washington D.C. to discuss the formation of interna-
tional working groups that can make recommendations
to address these hurdles, facilitate change and improve
the translation of novel immunotherapies to patients
with cancer. Through this international, collaborative
approach–marked by the establishment of the World
Immunotherapy Council–the many investigators and the
fifteen organizations involved in this initiative look for-
ward to combining their efforts synergistically to accel-
erate the delivery of promising new cancer
immunotherapies to patients around the world.
Consent
All individuals within the figures gave informed consent
for publication of their image.
Acknowledgements
This manuscript is the output of collaborative summits that were organized
and hosted by the Society for Immunotherapy of Cancer (SITC) at their 24th
and 25th Annual Meetings. BAF acknowledges support of Earle M. Chiles and
The Chiles Foundation, Robert W. Franz, Elsie Franz Finley, Lynn and Jack
Loacker, Wes and Nancy Lematta, the Safeway Foundation, and the
Providence Portland Medical Foundation. The work of CIMT-CIP was
supported by a grant from the Wallace Coulter foundation (Florida, USA).
The authors wish to acknowledge the following organizations, whose
representatives contributed to this manuscript:
∙ Society for Immunotherapy of Cancer (SITC; formerly the International
Society for Biological Therapy of Cancer, iSBTc)
∙ Association for Cancer Immunotherapy Immunoguiding Program (CIMT-CIP)
∙ Biotherapy Development Association (BDA)
∙ Canadian Cancer Immunotherapy Consortium (CCIC)
∙ Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute
(CRI)
∙ Chinese Society for Clinical Oncology (CSCO)
∙ Committee for Tumor Immunology and Bio-therapy (TIBT)
∙ Dutch Tumor Immunology Working Party (DTIWP)
∙ European Academy of Tumor Immunology (EATI)
∙ European Society for Cancer Immunology and Immunotherapy (ESCII)
∙ Italian Network for Tumor Biotherapy (NIBIT)
∙ Japanese Association of Cancer Immunology (JACI)
∙ Nordic Center for Development of Antitumour Vaccines (NCV-network)
∙ Progress in Vaccination Against Cancer (PIVAC)
∙ Tumor Vaccine and Cell Therapy Working Group (TVACT)
Author details
1Earle A. Chiles Research Institute, Robert W. Franz Research Center,
Providence Cancer Center, Providence Portland Medical Center, Portland, OR,
USA. 2Department of Molecular Microbiology and Immunology and Knight
Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
3Institute of Molecular Immunology and Clinical Cooperation Group
“Immune Monitoring”, Helmholtz Centre Munich, German Research Center
for Environmental Health, Munich, Germany. 4Departments of Medicine,
Division of Hematology Oncology, University of Pittsburgh Cancer Institute,
Pittsburgh, PA, USA. 5Department of Surgery University of Pittsburgh Cancer
Institute, Pittsburgh, PA, USA. 6Department of Immunology, University of
Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 7Department of Clinical
Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital,
Oslo, Norway. 8Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
9Howard Hughes Medical Institute, New York, NY, USA. 10Medical Oncology
and Innovative Therapy, Instituto Nazionale Tumori-Fondazione ‘G. Pascale’,
Naples, Italy. 11Beth Israel Deaconess Medical Center, Boston, MA, USA.
12Harvard Medical School, Boston, MA, USA. 13Institute of Immunology,
FOCIS Center of Excellence, 2nd Medical School, Charles University, Prague,
Czech Republic. 14Goethe Universität Frankfurt Am Main,Medizinische Klinik
II, Frankfurt Am Main, Germany. 15IRX Therapeutics, New York, NY, USA.
16Instituto Nacional para o Controle do Câncer, Instituto de Pesquisas
Biomédicas, PUCRS Faculdade de Biociências, PUCRS, Porto Alegre RS Brazil.
17Department of Translational Hematology and Oncology Research,
Cleveland Clinic, Cleveland, OH, USA. 18Department of Solid Tumor
Oncology, Cleveland Clinic, Cleveland, OH, USA. 19Department of Pathology,
McMaster University, Hamilton, ON, Canada. 20University Medical Center
Mainz, III. Medical Department, Mainz, Germany. 21Ribological GmbH, Mainz,
Germany. 22Chinese Academy of Medical Sciences, Beijing, China. 23Institute
of Immunology, National Key Laboratory of Medical Immunology, Second
Military Medical University, Shanghai, China. 24Department of Surgery, Ohio
State University, Columbus, OH, USA. 25Department of Surgery, University of
Michigan Medical Center, Ann Arbor, MI. 26Faculty of Medicine, Vilnius
University, Vilnius, Lithuania. 27University of Queensland, Brisbane, Australia.
28Ovarian Cancer Research Center, University of Pennsylvania Medical Center,
Philadelphia, A, USA. 29Department of Medical Oncology, VU Medical Center,
Cancer Center Amsterdam Amsterdam, The Netherlands. 30Hoag Institute for
Research and Education, Hoag Cancer Institute, Newport Beach, CA, USA.
31Department of Laboratory Medicine, Nijmegen Centre for Molecular Life
Sciences, Radboud University, Nijmegen Medical Centre, Nijmegen, The
Netherlands. 32Department of Medical Oncology, Dana-Farber Cancer
Institute, Boston, MA, USA. 33Department of Medicine, Brigham and
Women’s Hospital, Boston, MA, USA. 34Harvard Medical School, Boston, MA,
USA. 35Academic Department of Clinical Oncology, University of
Nottingham, Nottingham, UK. 36Department of Immunology, Cleveland
Clinic Foundation, Cleveland, OH, USA. 37INSERM U872, Cordeliers Research
Center, Paris, France. 38Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA.
39Institute for Cell Biology, Department of Immunology, University of
Tuebingen, Tuebingen, Germany. 40Istituto Clinico Humanitas, IRCCS, Milan,
Italy. 41Oncology Department, Oncology Institute Bari, Italy. 42University of
Lund, Lund, Sweden. 43CanImGuide Therapeutics AB, Hoellviken, Sweden.
44University of California, San Francisco, CA and Celgene Corporation, San
Francisco, CA, USA. 45Intrexon Corporation, Germantown,MD, USA.
46Department of Medicine, Harvard Medical School, Boston, MA, USA.
47Dana-Farber Cancer Institute, Boston, MA, USA. 48Bristol-Myers Squibb
Company, Wallingford, Connecticut, USA. 49Translational Oncology &
Immunology Centre TRON at the Mainz University Medical Center, Mainz,
Germany. 50Department of Melanoma Medical Oncology, MD Anderson
Fox et al. Journal of Translational Medicine 2011, 9:214
http://www.translational-medicine.com/content/9/1/214
Page 11 of 14
Cancer Center, Houston, TX, USA. 51The Institute of Medical Science, The
University of Tokyo, Tokyo, Japan. 52Department of Oncology, the Sidney
Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA. 53ZellNet
Consulting, Inc., Fort Lee, NJ, USA. 54Pathology and Laboratory Medicine,
University of Pennsylvania, Philadelphia, PA, USA. 55Rush University Cancer
Center, Rush University Medical Center, Chicago, IL, USA. 56School of
Medicine and Public Health, Kyoto University, Kyoto, Japan. 57Division of
Cellular Signaling, Institute for Advanced Medical Research, Keio University
School of Medicine, Tokyo, Japan. 58Dept. of Hematology and Medical
Oncology, Charité Comprehensive Cancer Center, Berlin, Germany. 59Cancer
Vaccine Section, NCI, NIH, Bethesda, MD, USA. 60Department of Oncology -
Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University
Hospital, Stockholm, Sweden. 61Department of Molecular Immunology and
Toxicology, Center of Surgical and Molecular Tumor pathology, National
Institute of Oncology, Budapest, Hungary. 62INSERM, U848, Institut Gustave
Roussy, Villejuif, France. 63Research Center, University Hospital, Université de
Montréal (CRCHUM), Montréal, Québec, Canada. 64Institut du Cancer de,
Montréal, Montréal, Québec, Canada. 65School of Medicine, Oncology Center,
Johns Hopkins University, Baltimore, MD, USA. 66Department of Molecular
Oncology, Foundation San Raffaele Scientific Institute, Milan, Italy. 67Medical
Oncology and Immunotherapy, Department of Oncology, University, Hospital
of Siena, Istituto Toscano Tumori, Siena, Italy. 68Merck KGaA, Darmstadt,
Germany. 69Department of Medical Oncology, Thomas Jefferson University,
Philadelphia, PA, USA. 70Department of Oncology-Pathology, Karolinska
Institute, Stockholm, Sweden. 71Department of Immunology, CIMA, CUN and
Medical School University of Navarra, Pamplona, Spain. 72Deptartment of
Immunohematology and Blood Transfusion, Leiden University Medical
Centre, Leiden, the Netherlands. 73University of California-Davis Medical
Center, Sacramento, CA, USA. 74Deeley Research Centre, BC Cancer Agency,
Victoria, BC, Canada. 75Department of Internal Medicine, University of Pisa,
Santa Chiara Hospital, Pisa, Italy. 76Oncology Institute, Loyola University
Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL, USA.
77Department of Gynecologic Oncology, Tumor Immunology and
Immunotherapy Program, Roswell Park Cancer Institute, Buffalo, NY, USA.
78Ontario Cancer Institute/University Health Network, Toronto, ON, Canada.
79Cancer Research Institute, New York, NY, USA. 80Ludwig Institute for Cancer
Research, New York, NY, USA. 81Experimental Cancer Medicine Centre,
University of Southampton Faculty of Medicine, Southampton, UK. 82Cancer
Immunology and Immunotherapy Center, Saint Savas Cancer Hospital,
Athens, Greece. 83Unit of Immuno-Biotherapy of Melanoma and Solid
Tumors, San Raffaele Scientific Institute, Milan, Italy. 84Center for Medical
Research, University of Tuebingen, Tuebingen, Germany. 85Istituto Superiore
di Sanita’, Rome, Italy. 86Chinese PLA Cancer Center, Nanjing, China. 87The
John van Geest Cancer Research Centre, School of Science and Technology,
Nottingham Trent University, Nottingham, UK. 88Department of Medicine,
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA.
89Immunoterapia e Terapia Cellulare Somatica, Istituto Scientifico Romagnolo
per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy. 90Unit of
Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale
Tumori, Milan, Italy. 91Division of Clinical Onco-Immunology, Ludwig Center
for Cancer Research of the University of Lausanne, Epalinges, Switzerland.
92Immunology and Biotechnology Unit, Department of Zoology, Faculty of
Science, Tanta University, Egypt. 93Dept. of Pathology, VU University Medical
Center, Amsterdam, The Netherlands. 94Institute of Medical Immunology,
Halle, Germany. 95MD Anderson Cancer Center, Houston, TX, USA.
96Department of Cancer Vaccine, Mie University Graduate School of
Medicine, Mie, Japan. 97Department of Immuno-gene Therapy, Mie
University Graduate School of Medicine, Mie, Japan. 98Immatics
Biotechnologies GmbH, Tübingen, Germany. 99Millennium: The Takeda
Oncology Company, Cambridge, MA, USA. 100Center for Cancer Immune
Therapy (CCIT), Department of Hematology, Herlev Hospital, Herlev,
Denmark. 101Department of Surgery and Bioengineering, Advanced Clinical
Research Center, Institute of Medical Science, The University of Tokyo, Tokyo,
Japan. 102Institute of Immunology, School of Life Sciences, University of
Science & Technology of China, Hefei, China. 103Institute of
Immunopharmacology & Immunotherapy, School of Pharmaceutical
Sciences, Shandong University, Jinan, China. 104Experimental Cancer
Immunology and Therapy, Department of Clinical Oncology, Leiden
University Medical Center, Leiden, Netherlands. 105Euraccine Consulting
Group, Brussels, Belgium. 106Infectious Disease and Immunogenetics Section
(IDIS), Department of Transfusion Medicine, Clinical Center, NIH, Bethesda,
MD, USA. 107Center for Human Immunology (CHI), NIH, Bethesda, MD, USA.
108Experimental Cancer Immunology and Therapy, Department of Clinical
Oncology (K1-P), Leiden University Medical Center, Leiden, The Netherlands.
109Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians
University, Munich, Germany. 110Society for Immunotherapy of Cancer,
Milwaukee, WI, USA. 111Institute of Immunology, School of Life Science,
University of Science and Technology of China, Hefei, China. 112Institut
Gustave Roussy, Center of Clinical Investigations CICBT507, Villejuif, France.
113Department Haematology and Oncology Innsbruck Medical University,
Innsbruck, Austria. 114University of Chicago Medical Center, Chicago, IL, USA.
115Discovery Medicine-Oncology, Bristol-Myers Squibb Company, Princeton,
New Jersey, USA. 116Tumor Vaccine Group, Center for Translational Medicine
in Women’s Health, University of Washington, Seattle, WA, USA.
Authors’ contributions
BF prepared the manuscript collaboratively with input and review by all co-
authors representing their respective organizations. All authors have read
and approved the final manuscript.
Competing interests
BAF - Co-Founder UbiVac, SAB Micromet, SAB MannKind; PAA - participated
in advisory board for Bristol Myers Squibb, GSK, Schering-Plough/Merck and
Roche. He has received honoraria from Bristol Myers Squibb and Schering-
Plough/Merck; NLB - employee of IRX Therapeutics, scientific advisor for
Immunovaccine Technologies and Roche Canada, stock options for sanofi
Aventis; CMB is an employee of Ribological GmbH; JAG - Employee of
Alnylam Pharmaceuticals; KH - employee and stockholder of Celgene
Corporation; RBH - Employee of Intrexon Corporation; AH - Employee Bristol-
Myers Squibb; SJ - Founder and president of ZellNet Consulting; HIL -
Employee of Roche; J-PM - Employee of Merck KGaA; HS-J - Co-founder and
employee of Immatics Biotechnologies GmbH; WS - Employee of Takeda
Pharmaceuticals; JMW - Employee Bristol-Myers Squibb; All other authors -
No competing interests.
Received: 2 May 2011 Accepted: 14 December 2011
Published: 14 December 2011
References
1. Ferlay J, Shin HR, Bray F, et al: Cancer Incidence and Mortality Worldwide:
IARC CancerBase No. 10 [Internet]. International Agency for Research on
Cancer 2010 [http://globocan.iarc.fr], 2010.
2. Milken M: Health-Care Investment - The Hidden Crisis. The Wall Street
Journal 2011.
3. Dillman RO, Fogel GB, Cornforth AN, et al: Features associated with
survival in metastatic melanoma patients treated with patient-specific
dendritic cell vaccines. Cancer biotherapy & radiopharmaceuticals 2011,
26:407-15.
4. Mlecnik B, Tosolini M, Kirilovsky A, et al: Histopathologic-based prognostic
factors of colorectal cancers are associated with the state of the local
immune reaction. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2011, 29:610-8.
5. Broussard EK, Disis ML: TNM staging in colorectal cancer: T is for T cell
and M is for memory. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2011, 29:601-3.
6. O’Donnell PH, Dolan ME: Cancer pharmacoethnicity: ethnic differences in
susceptibility to the effects of chemotherapy. Clin Cancer Res 2009,
15:4806-14.
7. Baiocchi M, Biffoni M, Ricci-Vitiani L, et al: New models for cancer research:
human cancer stem cell xenografts. Curr Opin Pharmacol 2010, 10:380-4.
8. Bankert RB, Hess SD, Egilmez NK: SCID mouse models to study human
cancer pathogenesis and approaches to therapy: potential, limitations,
and future directions. Front Biosci 2002, 7:c44-62.
9. Ishikawa F, Yasukawa M, Lyons B, et al: Development of functional human
blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain
(null) mice. Blood 2005, 106:1565-73.
10. Stauffer JK, Scarzello AJ, Andersen JB, et al: Coactivation of AKT and beta-
catenin in mice rapidly induces formation of lipogenic liver tumors.
Cancer research 2011, 71:2718-27.
11. Romer PS, Berr S, Avota E, et al: Preculture of PBMC at high cell density
increases sensitivity of T-cell responses, revealing cytokine release by
CD28 superagonist TGN1412. Blood 2011.
Fox et al. Journal of Translational Medicine 2011, 9:214
http://www.translational-medicine.com/content/9/1/214
Page 12 of 14
12. Morgan RA, Yang JC, Kitano M, et al: Case report of a serious adverse
event following the administration of T cells transduced with a chimeric
antigen receptor recognizing ERBB2. Molecular therapy : the journal of the
American Society of Gene Therapy 2010, 18:843-51.
13. Brentjens R, Yeh R, Bernal Y, et al: Treatment of chronic lymphocytic
leukemia with genetically targeted autologous T cells: case report of an
unforeseen adverse event in a phase I clinical trial. Molecular therapy : the
journal of the American Society of Gene Therapy 2010, 18:666-8.
14. Butterfield LH, Disis ML, Fox BA, et al: A systematic approach to biomarker
discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy
biomarkers”. J Transl Med 2008, 6:81.
15. Visvader JE: Cells of origin in cancer. Nature 469:314-22.
16. Damia G, D’Incalci M: Genetic instability influences drug response in
cancer cells. Curr Drug Targets 11:1317-24.
17. Fisher DE, Barnhill R, Hodi FS, et al: Melanoma from bench to bedside:
meeting report from the 6th international melanoma congress. Pigment
Cell Melanoma Res 2010, 23:14-26.
18. Ko JM, Fisher DE: A new era: melanoma genetics and therapeutics. J
Pathol 2011, 223:241-50.
19. Finak G, Bertos N, Pepin F, et al: Stromal gene expression predicts clinical
outcome in breast cancer. Nat Med 2008, 14:518-27.
20. Butterfield LH, Palucka AK, Britten CM, et al: Recommendations from the
iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical
cancer research : an official journal of the American Association for Cancer
Research 2011, 17:3064-3076.
21. Gajewski TF, Louahed J, Brichard VG: Gene signature in melanoma
associated with clinical activity: a potential clue to unlock cancer
immunotherapy. Cancer J 16:399-403.
22. Liakou CI, Kamat A, Tang DN, et al: CTLA-4 blockade increases IFNgamma-
producing CD4+ICOShi cells to shift the ratio of effector to regulatory T
cells in cancer patients. Proceedings of the National Academy of Sciences of
the United States of America 2008, 105:14987-92.
23. Carthon BC, Wolchok JD, Yuan J, et al: Preoperative CTLA-4 blockade:
tolerability and immune monitoring in the setting of a presurgical
clinical trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2010, 16:2861-71.
24. Sharma P, Wagner K, Wolchok JD, et al: Novel cancer immunotherapy
agents with survival benefit: recent successes and next steps. Nature
reviews Cancer 2011, 11:805-12.
25. Koebel CM, Vermi W, Swann JB, et al: Adaptive immunity maintains occult
cancer in an equilibrium state. Nature 2007, 450:903-7.
26. Ferrone C, Dranoff G: Dual roles for immunity in gastrointestinal cancers.
J Clin Oncol 28:4045-51.
27. Schreiber TH, Podack ER: A critical analysis of the tumour
immunosurveillance controversy for 3-MCA-induced sarcomas. Br J
Cancer 2009, 101:381-6.
28. Lake RA, Robinson BW: Immunotherapy and chemotherapy–a practical
partnership. Nat Rev Cancer 2005, 5:397-405.
29. Zitvogel L, Apetoh L, Ghiringhelli F, et al: The anticancer immune
response: indispensable for therapeutic success? J Clin Invest 2008,
118:1991-2001.
30. Demaria S, Formenti SC: Sensors of ionizing radiation effects on the
immunological microenvironment of cancer. International journal of
radiation biology 2007, 83:819-25.
31. Zitvogel L, Kepp O, Kroemer G: Immune parameters affecting the efficacy
of chemotherapeutic regimens. Nature reviews. Clinical oncology 2011,
8:151-60.
32. Begley J, Ribas A: Targeted therapies to improve tumor immunotherapy.
Clinical cancer research : an official journal of the American Association for
Cancer Research 2008, 14:4385-91.
33. Harzstark AL, Small EJ: Immunotherapeutics in development for prostate
cancer. Oncologist 2009, 14:391-8.
34. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity
induced by cytotoxic T lymphocyte-associated antigen 4 blockade in
patients with metastatic melanoma. Proc Natl Acad Sci USA 2003,
100:8372-7.
35. Hodi FS, Butler M, Oble DA, et al: Immunologic and clinical effects of
antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in
previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008,
105:3005-10.
36. Cheever MA: Twelve immunotherapy drugs that could cure cancers.
Immunol Rev 2008, 222:357-68.
37. Cheever MA, Schlom J, Weiner LM, et al: Translational Research Working
Group developmental pathway for immune response modifiers. Clin
Cancer Res 2008, 14:5692-9.
38. Cheever MA, Allison JP, Ferris AS, et al: The prioritization of cancer
antigens: a national cancer institute pilot project for the acceleration of
translational research. Clin Cancer Res 2009, 15:5323-37.
39. Korman AJ, Melero I, Okada H, et al: Workshop on Immunotherapy
Combinations. 2011.
40. Lonchay C, van der Bruggen P, Connerotte T, et al: Correlation between
tumor regression and T cell responses in melanoma patients vaccinated
with a MAGE antigen. Proceedings of the National Academy of Sciences of
the United States of America 2004, 101 Suppl 2:14631-8.
41. Lurquin C, Lethe B, De Plaen E, et al: Contrasting frequencies of antitumor
and anti-vaccine T cells in metastases of a melanoma patient vaccinated
with a MAGE tumor antigen. The Journal of experimental medicine 2005,
201:249-57.
42. Britten CM, Gouttefangeas C, Welters MJ, et al: The CIMT-monitoring panel:
a two-step approach to harmonize the enumeration of antigen-specific
CD8+ T lymphocytes by structural and functional assays. Cancer
immunology, immunotherapy : CII 2008, 57:289-302.
43. Britten CM, Janetzki S, Ben-Porat L, et al: Harmonization guidelines for
HLA-peptide multimer assays derived from results of a large scale
international proficiency panel of the Cancer Vaccine Consortium. Cancer
Immunol Immunother 2009, 58:1701-13.
44. Hodi FS, O’Day SJ, McDermott DF, et al: Improved survival with
ipilimumab in patients with metastatic melanoma. The New England
journal of medicine 2010, 363:711-23.
45. Janetzki S, Britten CM: The impact of harmonization on ELISPOT assay
performance. Methods in molecular biology 2012, 792:25-36.
46. Rosenberg SA, Dudley ME: Cancer regression in patients with metastatic
melanoma after the transfer of autologous antitumor lymphocytes. Proc
Natl Acad Sci USA 2004, 101(Suppl 2):14639-45.
47. Kirkwood JM, Lee S, Moschos SJ, et al: Immunogenicity and antitumor
effects of vaccination with peptide vaccine+/-granulocyte-monocyte
colony-stimulating factor and/or IFN-alpha2b in advanced metastatic
melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
Clin Cancer Res 2009, 15:1443-51.
48. McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful
cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005,
97:1023-5.
49. Lee JA, Spidlen J, Boyce K, et al: MIFlowCyt: the minimum information
about a Flow Cytometry Experiment. Cytometry A 2008, 73:926-30.
50. Mehrle A, Rosenfelder H, Weiman S: MIACA - Minimum Information About
a Cellular Assay. 2009.
51. Janetzki S, Britten CM, Kalos M, et al: “MIATA"-minimal information about
T cell assays. Immunity 2009, 31:527-8.
52. Hoos A, Parmiani G, Hege K, et al: A clinical development paradigm for
cancer vaccines and related biologics. J Immunother 2007, 30:1-15.
53. Hales RK, Banchereau J, Ribas A, et al: Assessing oncologic benefit in
clinical trials of immunotherapy agents. Ann Oncol 2010, 21:1944-51.
54. Hoos A, Eggermont AM, Janetzki S, et al: Improved endpoints for cancer
immunotherapy trials. J Natl Cancer Inst 2010, 102:1388-97.
55. Wolchok JD, Hoos A, O’Day S, et al: Guidelines for the evaluation of
immune therapy activity in solid tumors: immune-related response
criteria. Clin Cancer Res 2009, 15:7412-20.
56. Finke LH, Wentworth K, Blumenstein B, et al: Lessons from randomized
phase III studies with active cancer immunotherapies-outcomes from
the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007,
25:B97-B109, (suppl 2). 25:B97-B109 (suppl 2). 2007.
57. Hoos A, Britten CM, Huber C, et al: A methodological framework to
enhance the clinical success of cancer immunotherapy. Nature
biotechnology 2011, 29:867-70.
58. FDA: Draft Guidance for Industry: Clinical Considerations for Therapeutic
Cancer Vaccines. 2009.
59. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. The New England journal of medicine
2010, 363:411-22.
60. Yuan J, Adamow M, Ginsberg BA, et al: Integrated NY-ESO-1 antibody and
CD8+ T-cell responses correlate with clinical benefit in advanced
Fox et al. Journal of Translational Medicine 2011, 9:214
http://www.translational-medicine.com/content/9/1/214
Page 13 of 14
melanoma patients treated with ipilimumab. Proceedings of the National
Academy of Sciences of the United States of America 2011, 108:16723-8.
61. Carpenter S: Science careers. Carving a career in translational research.
Science 2007, 317:966-7.
62. Disis ML, Slattery JT: The road we must take: multidisciplinary team
science. Sci Transl Med 2:22cm9.
63. SITC: Leading Cancer Immunotherapy Scientists and Research Teams
Honored at iSBTc 25th Annual Meeting. 2010.
doi:10.1186/1479-5876-9-214
Cite this article as: Fox et al.: Defining the critical hurdles in cancer
immunotherapy. Journal of Translational Medicine 2011 9:214.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fox et al. Journal of Translational Medicine 2011, 9:214
http://www.translational-medicine.com/content/9/1/214
Page 14 of 14
